Novel Therapies and Stem Cell Transplant for Multiple Myeloma
Read Transcript
Download Transcript 
Share This Video
Take Our SurveyDr. Robert Orlowski, head of the myeloma section at MD Anderson Cancer Center, details a number of updates from the 2011 American Society of Hematology meeting. He explains data presented regarding newer drugs carfilzomib and bortezomib and a range of studies looking at consolidation and maintenance therapy following a stem cell transplant. He also talks about the expansion of newer tests to detect Minimal Residual Disease or MRD.
Health Topics: Multiple Myeloma
Get Email Updates:
Get updated automatically when new content about Multiple Myeloma has been posted.
Privacy Policy
Privacy Policy
Multiple Myeloma
Experts & Guests
|
Robert Orlowski, M.D., Ph.D.
Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, MD Anderson Cancer Center
Dr. Robert Z. Orlowski is Associate Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the...
more >
|
|
|
